Company Overview and News

 
The India Cements Limited - Change in Director(s)

2018-10-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIACEM 530005

 
The India Cements Limited - Updates

2018-10-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIACEM 530005

 
The India Cements Limited - Shareholders meeting

2018-09-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIACEM 530005

 
The India Cements Limited - Shareholders meeting

2018-09-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIACEM 530005

 
Coal import scam: Adani group gets interim relief from DRI

2018-09-19 moneycontrol
The Bombay High Court on Wednesday granted interim relief to the Adani group by restraining the Directorate of Revenue Intelligence (DRI) from giving effect to the letters rogatory (LRs) issued to several countries against three group companies in an alleged case of overvaluation of Indonesian coal imports in the past.
ANNRY ADANIENT 500228 INDIACEM 530005 512599 JSWSTEEL JSWENERGY 533148

 
D-Street Buzz: FMCG stocks fall dragged by Jubilant Food, HUL; IT stocks rally with Infosys up 3%, hits new 52-week high

2018-09-04 moneycontrol
The market sentiment is negative this Tuesday morning after the rupee slipped to yet another record low against the US dollar. The benchmark indices including the Nifty50 shed 42 points at 11,540 while the Sensex is trading lower by 86 points at 38,226.
500325 DABUR BRIGADE BRTQY TCHQY TTQQY 532755 DBRQY 532710 TATACHEM SYNDIBANK 500096 532483 500696 BRITANNIA 500770 502355 RLNIY SBAZ RELCAPITAL YYBKY 530005 ALBERTDA CNRYY TECHM 532276 TCS CANBK ANDHRABANK BALKRISIND 500825 RELIANCE 532418 HINDUNILVR 533155 TATACOMM NAUKRI TTNQY JUBLFOOD 532777 532540 RIGD JBLWY SADBHAV INDIACEM 500111 YESBANK UBNC 517354 HVLQY 532929 532648 524075 HAVELLS 501455 GREAVESCOT 500483

 
D-Street Buzz: IT, pharma stocks gain on weak rupee led by Infosys, Dr Reddy#39;s Labs; Infosys, ITC at new 52-week high

2018-08-31 moneycontrol
The Indian market after opening flat has managed to move higher this Friday morning with the Nifty50 up 47 points at 11,724 while the Sensex is trading higher by 127 points at 38,817.
AMKD 500408 BHRYY AUROPHARMA GODREJIND PQRTY TCHQY PRMQY AMTEKAUTO ICLQY 532832 532755 CADILAHC 532321 534816 INFRATEL INDIACEM UNIVCABLES 504212 524804 PETRONET 532822 530005 PEL CDLYY 532522 TECHM ARBQY IDEA TATAELXSI 500302 520077 500164 IBREALEST

 
The India Cements Limited - Updates

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INDIACEM 530005

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...